We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

12 hedge funds and large institutions have $5.09M invested in Outlook Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more capital inflows, than outflows

Capital inflows: $371K | Capital outflows: $323K

9% more funds holding

Funds holding: 11 → 12 (+1)

0.07% more ownership

Funds ownership: 7.07% → 7.15% (+0.07%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
12
Holders Change
+1
Holders Change %
+9.09%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$232K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$136K
3
Bank of America
Bank of America
North Carolina
+$2.11K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$297K
2
Panagora Asset Management
Panagora Asset Management
Massachusetts
-$20.1K
3
Two Sigma Securities
Two Sigma Securities
New York
-$3.94K
4
UBS Group
UBS Group
Switzerland
-$1.69K

OTLK Hedge Fund Activity: Q3 2018 in Review

12 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q3 2018, worth a combined $5.09M — up 18% from $4.31M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new OTLK positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $232K. The largest seller was Sabby Management, cutting an estimated $297K.

  • 12 institutional investors held Outlook Therapeutics (OTLK) as of Q3 2018, up from 11 in Q2 2018.
  • Funds reported $5.09M of Outlook Therapeutics stock for Q3 2018, up 18% quarter-over-quarter.
  • 1 fund opened new Outlook Therapeutics positions in Q3 2018 and 0 closed out, a net change of +1 holder.
  • The largest Outlook Therapeutics buyer in Q3 2018 was Vanguard Group, an estimated $232K added.
  • The largest Outlook Therapeutics seller in Q3 2018 was Sabby Management, an estimated $297K sold.

Based on aggregated 13F filings for Q3 2018.